Radius Health, Inc (RDUS)

Etorro trading 970x250
Radius Health, Inc (RDUS) Logo

About Radius Health, Inc

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210

Radius Health, Inc News and around…

Latest news about Radius Health, Inc (RDUS) common stock and company :

RDUS Makes Notable Cross Below Critical Moving Average
18 Nov, 2021 FinancialContent

In trading on Thursday, shares of Radius Health Inc (RDUS) crossed below their 200 day moving average of $18.03, changing hands as low as $17.73 per share. Radius Health Inc shares are currently trading down about 2% on the day..

These 40 Mass. companies made the new Deloitte Fast 500 list
17 Nov, 2021 Yahoo! Finance

The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.

Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference
11 Nov, 2021 Yahoo! Finance

BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference, including a fireside chat at 8:40 a.m. ET on Tuesday, November 16, 2021, followed by investor meetings. A live webcast of the fireside chat will be available by visiting the Investors section of the Company’s website at https://ir.radiuspharm.com/events-and-presentations. A replay of the webcast

What 5 Analyst Ratings Have To Say About Radius Health
09 Nov, 2021 FinancialContent

Over the past 3 months, 5 analysts have published their opinion on Radius Health (NASDAQ:RDUS) stock. These analysts are typically ...

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines
09 Nov, 2021 Yahoo! Finance

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

Radius Health (RDUS) Q3 2021 Earnings Call Transcript
09 Nov, 2021 FinancialContent

RDUS earnings call for the period ending September 30, 2021.

Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates
08 Nov, 2021 Yahoo! Finance

Radius Health (RDUS) delivered earnings and revenue surprises of -74.07% and -7.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Radius Health, Inc.: Third Quarter 2021 Results
08 Nov, 2021 Yahoo! Finance

TYMLOS® Q3, 2021 net revenue: $57 million, +13% vs. Q3, 2020Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included elacestrant license revenueATOM Pivotal Study evaluating abaloparatide-SC for use in males with osteoporosis met primary and key secondary endpoints; sNDA filing is expected Q1, 2022Resubmitted abaloparatide-SC to the European Medicines Agency (EMA) on November 4, 2021wearABLe Pivotal Study (abalopa

Earnings Scheduled For November 8, 2021
08 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 ...

Earnings Outlook For Radius Health
05 Nov, 2021 FinancialContent

Radius Health (NASDAQ:RDUS) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to ...

Earnings Preview: Radius Health (RDUS) Q3 Earnings Expected to Decline
01 Nov, 2021 Yahoo! Finance

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hedge Funds Are Selling Radius Health Inc (RDUS)
29 Oct, 2021 Yahoo! Finance

In this article you are going to find out whether hedge funds think Radius Health Inc (NASDAQ:RDUS) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Radius Health Shows Market Leadership With Jump To 81 RS Rating
26 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Radius Health shows improving technical performance.

Radius Health Trying To Close In On Key Technical Benchmark
25 Oct, 2021 FinancialContent

Radius Health shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

CORRECTING and REPLACING -- Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
21 Oct, 2021 Yahoo! Finance

BOSTON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346) 406-0961 for international calls. The conference ID remains the same, 9322858. The corrected release appears below: Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial r

Analyst Ratings For Radius Health
21 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Radius Health (NASDAQ:RDUS) within the last quarter: Bullish Somewhat ...

Radius (RDUS) Up On Positive Data From Breast Cancer Study
21 Oct, 2021 Yahoo! Finance

Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.

48 Biggest Movers From Yesterday
21 Oct, 2021 FinancialContent

Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares surged 98.4% to settle at $18.87 on Wednesday on above-average volume. The company ...

Noteworthy Wednesday Option Activity: RDUS, WWD, EGHT
20 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Radius Health Inc (RDUS), where a total of 21,034 contracts have traded so far, representing approximately 2.1 million underlying shares. That amounts to about 432.8% of RDUS's average daily trading volume over the past month of 485,985 shares..

Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
20 Oct, 2021 Yahoo! Finance

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update. Conference Call Information:Domestic Dial-In Number: 1 (855) 404-2458International Dial-In Number: 1 (430) 775-1272Conference ID: 9322858Webcast Link: https://edge.media-server.com/mmc/p/94

Mid-Afternoon Market Update: Nasdaq Turns Lower; Sesen Bio Shares Surge
20 Oct, 2021 FinancialContent

Toward the end of trading Wednesday, the Dow traded up 0.46% to 35,619.52 while the NASDAQ fell 0.19% to 15,100.51. The S&P also ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Oct, 2021 FinancialContent

Gainers Sesen Bio (NASDAQ:SESN) stock increased by 29.2% to $1.3 during Wednesday's regular session. Trading volume ...

Mid-Day Market Update: Healthcare Services Drops After Q3 Results; Radius Health Shares Jump
20 Oct, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded up 0.40% to 35,598.89 while the NASDAQ rose 0.15% to 15,151.71. The S&P also rose, ...

Why Radius Health Stock Is Exploding Higher Today
20 Oct, 2021 FinancialContent

Positive clinical-trial results for a late-stage breast cancer treatment are pushing the stock up.

32 Stocks Moving In Wednesday's Mid-Day Session
20 Oct, 2021 FinancialContent

Gainers Sesen Bio, Inc. (NASDAQ: SESN) rose 34.7% to $1.36. The FDA granted Sesen Bio’s request for a Type A meeting to ...

Mid-Morning Market Update: Markets Open Higher; Verizon Posts Upbeat Earnings
20 Oct, 2021 FinancialContent

Following the market opening Wednesday, the Dow traded up 0.35% to 35,580.21 while the NASDAQ rose 0.11% to 15,146.02. The S&P also ...

Why Are Radius Health Shares Soaring Today?
20 Oct, 2021 FinancialContent

TheMenarini GroupandRadius Health Inc(NASDAQ: RDUS) haveannounced topline resultsfrom the EMERALD ...

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
20 Oct, 2021 Yahoo! Finance

Study met both primary endpoints in patients with ER+/HER2- advanced or mBCElacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBCElacestrant extended PFS in the overall population and the ESR1 mutation subgroupPlans for regulatory submissions in both the United States and Europe in 2022Data planned to be presented at the San Antonio Breast Cancer Symposium in December, 2021 FLORENCE, Italy

Radius Health Reports Positive Phase 3 Cancer Treatment Trial Results
20 Oct, 2021 Yahoo! Finance

By Sam Boughedda

Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal
19 Oct, 2021 Yahoo! Finance

Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

Radius Health, Inc (RDUS) is a NASDAQ Common Stock listed in , ,

970x250